Trials / Completed
CompletedNCT04051606
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Case Comprehensive Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of Regorafenib in patients with recurrent or progressive glioblastoma (GBM) who have progressed on bevacizumab. Regorafenib is FDA approved administered as monotherapy during the study. 22 total patients are expected to participate in this study. Even though a participant may meet all the criteria for participation, it is possible that they will not be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Regorafenib | Regorafenib is a monotherapy during the study, oral administration at 160 mg once daily will be administered for 3 weeks on /1 week off. |
Timeline
- Start date
- 2019-07-31
- Primary completion
- 2024-03-20
- Completion
- 2024-03-20
- First posted
- 2019-08-09
- Last updated
- 2025-06-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04051606. Inclusion in this directory is not an endorsement.